Plasma Levels of Complement Factor i and C4b Peptides Are Associated with HIV Suppression

Boyue Wu, Zhengyu Ouyang, Christopher J. Lyon, Wei Zhang, Tori Clift, Christopher R. Bone, Boan Li, Zhen Zhao, Jason T. Kimata, Xu G. Yu, Ye Hu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Individuals who exhibit long-term HIV suppression and CD4 T-cell preservation without antiretroviral therapy are of great interest for HIV research. There is currently no robust method for rapid identification of these "HIV controller" subjects; however, HLA-B∗57 (human leukocyte antigen (major histocompatibility complex), class I, B∗57) genotype exhibits modest sensitivity for this phenotype. Complement C3b and C4b can influence HIV infection and replication, but studies have not examined their possible link to HIV controller status. We analyzed HLA-B∗57 genotype and complement levels in HIV-positive patients receiving suppressive antiretroviral therapy, untreated HIV controllers, and HIV-negative subjects to identify factors associated with HIV controller status. Our results revealed that the plasma levels of three C4b-derived peptides and complement factor I outperformed all other assayed biomarkers for HIV controller identification, although we could not analyze the predictive value of biomarker combinations with the current sample size. We believe this rapid screening approach may prove useful for improved identification of HIV controllers.

Original languageEnglish (US)
Pages (from-to)880-885
Number of pages6
JournalACS Infectious Diseases
Volume3
Issue number12
DOIs
StatePublished - Dec 8 2017

Fingerprint

HIV
Peptides
Complement C4b
Complement Factor I
Biomarkers
Genotype
Complement C3b
HLA Antigens
Major Histocompatibility Complex
Sample Size
HIV Infections
T-Lymphocytes
Phenotype
Therapeutics
Research

Keywords

  • complement C4b
  • complement factor I
  • elite controllers
  • human immunodeficiency virus

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Plasma Levels of Complement Factor i and C4b Peptides Are Associated with HIV Suppression. / Wu, Boyue; Ouyang, Zhengyu; Lyon, Christopher J.; Zhang, Wei; Clift, Tori; Bone, Christopher R.; Li, Boan; Zhao, Zhen; Kimata, Jason T.; Yu, Xu G.; Hu, Ye.

In: ACS Infectious Diseases, Vol. 3, No. 12, 08.12.2017, p. 880-885.

Research output: Contribution to journalArticle

Wu, B, Ouyang, Z, Lyon, CJ, Zhang, W, Clift, T, Bone, CR, Li, B, Zhao, Z, Kimata, JT, Yu, XG & Hu, Y 2017, 'Plasma Levels of Complement Factor i and C4b Peptides Are Associated with HIV Suppression', ACS Infectious Diseases, vol. 3, no. 12, pp. 880-885. https://doi.org/10.1021/acsinfecdis.7b00042
Wu, Boyue ; Ouyang, Zhengyu ; Lyon, Christopher J. ; Zhang, Wei ; Clift, Tori ; Bone, Christopher R. ; Li, Boan ; Zhao, Zhen ; Kimata, Jason T. ; Yu, Xu G. ; Hu, Ye. / Plasma Levels of Complement Factor i and C4b Peptides Are Associated with HIV Suppression. In: ACS Infectious Diseases. 2017 ; Vol. 3, No. 12. pp. 880-885.
@article{bb10e3b1d9234a92b9acdaea31293548,
title = "Plasma Levels of Complement Factor i and C4b Peptides Are Associated with HIV Suppression",
abstract = "Individuals who exhibit long-term HIV suppression and CD4 T-cell preservation without antiretroviral therapy are of great interest for HIV research. There is currently no robust method for rapid identification of these {"}HIV controller{"} subjects; however, HLA-B∗57 (human leukocyte antigen (major histocompatibility complex), class I, B∗57) genotype exhibits modest sensitivity for this phenotype. Complement C3b and C4b can influence HIV infection and replication, but studies have not examined their possible link to HIV controller status. We analyzed HLA-B∗57 genotype and complement levels in HIV-positive patients receiving suppressive antiretroviral therapy, untreated HIV controllers, and HIV-negative subjects to identify factors associated with HIV controller status. Our results revealed that the plasma levels of three C4b-derived peptides and complement factor I outperformed all other assayed biomarkers for HIV controller identification, although we could not analyze the predictive value of biomarker combinations with the current sample size. We believe this rapid screening approach may prove useful for improved identification of HIV controllers.",
keywords = "complement C4b, complement factor I, elite controllers, human immunodeficiency virus",
author = "Boyue Wu and Zhengyu Ouyang and Lyon, {Christopher J.} and Wei Zhang and Tori Clift and Bone, {Christopher R.} and Boan Li and Zhen Zhao and Kimata, {Jason T.} and Yu, {Xu G.} and Ye Hu",
year = "2017",
month = "12",
day = "8",
doi = "10.1021/acsinfecdis.7b00042",
language = "English (US)",
volume = "3",
pages = "880--885",
journal = "ACS Infectious Diseases",
issn = "2373-8227",
publisher = "American Chemical Society",
number = "12",

}

TY - JOUR

T1 - Plasma Levels of Complement Factor i and C4b Peptides Are Associated with HIV Suppression

AU - Wu, Boyue

AU - Ouyang, Zhengyu

AU - Lyon, Christopher J.

AU - Zhang, Wei

AU - Clift, Tori

AU - Bone, Christopher R.

AU - Li, Boan

AU - Zhao, Zhen

AU - Kimata, Jason T.

AU - Yu, Xu G.

AU - Hu, Ye

PY - 2017/12/8

Y1 - 2017/12/8

N2 - Individuals who exhibit long-term HIV suppression and CD4 T-cell preservation without antiretroviral therapy are of great interest for HIV research. There is currently no robust method for rapid identification of these "HIV controller" subjects; however, HLA-B∗57 (human leukocyte antigen (major histocompatibility complex), class I, B∗57) genotype exhibits modest sensitivity for this phenotype. Complement C3b and C4b can influence HIV infection and replication, but studies have not examined their possible link to HIV controller status. We analyzed HLA-B∗57 genotype and complement levels in HIV-positive patients receiving suppressive antiretroviral therapy, untreated HIV controllers, and HIV-negative subjects to identify factors associated with HIV controller status. Our results revealed that the plasma levels of three C4b-derived peptides and complement factor I outperformed all other assayed biomarkers for HIV controller identification, although we could not analyze the predictive value of biomarker combinations with the current sample size. We believe this rapid screening approach may prove useful for improved identification of HIV controllers.

AB - Individuals who exhibit long-term HIV suppression and CD4 T-cell preservation without antiretroviral therapy are of great interest for HIV research. There is currently no robust method for rapid identification of these "HIV controller" subjects; however, HLA-B∗57 (human leukocyte antigen (major histocompatibility complex), class I, B∗57) genotype exhibits modest sensitivity for this phenotype. Complement C3b and C4b can influence HIV infection and replication, but studies have not examined their possible link to HIV controller status. We analyzed HLA-B∗57 genotype and complement levels in HIV-positive patients receiving suppressive antiretroviral therapy, untreated HIV controllers, and HIV-negative subjects to identify factors associated with HIV controller status. Our results revealed that the plasma levels of three C4b-derived peptides and complement factor I outperformed all other assayed biomarkers for HIV controller identification, although we could not analyze the predictive value of biomarker combinations with the current sample size. We believe this rapid screening approach may prove useful for improved identification of HIV controllers.

KW - complement C4b

KW - complement factor I

KW - elite controllers

KW - human immunodeficiency virus

UR - http://www.scopus.com/inward/record.url?scp=85038217749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038217749&partnerID=8YFLogxK

U2 - 10.1021/acsinfecdis.7b00042

DO - 10.1021/acsinfecdis.7b00042

M3 - Article

VL - 3

SP - 880

EP - 885

JO - ACS Infectious Diseases

JF - ACS Infectious Diseases

SN - 2373-8227

IS - 12

ER -